Tag:
Jevtana
Latest Headlines
Latest Headlines
NICE rejects J&J's Zytiga as too expensive
The U.K.'s cost-effectiveness gatekeepers want to shut out Johnson & Johnson's ( $JNJ ) new prostate cancer pill. The National Institute for Health and Clinical Excellence issued draft...
NICE nixes Sanofi's Jevtana on cost, side effects
The U.K.'s cost-effectiveness watchdog has officially snubbed the Sanofi ( $SNY ) prostate cancer treatment Jevtana. The National Institute for Health and Clinical Excellence won't recommend the drug
